ETN - UBS BIOTEC 27 Jun28
 
Focus and Objective
Investors in biotechnology have experienced turbulent performance over the last couple of years. Like many growth sectors, performance lagged the wider market in 2021 and the first half of 2022, as central bank hiking led to heavier discounting of future cashflows and lower valuations. The structural investment case remains: demographic trends driving demand for cures, rising costs may drive regulatory pragmatism to potentially endorse biotechnology tools that improve health outcomes and incentive for large- cap pharma and biotech firms to acquire faster-growing smaller firms looks set to intensify. The Bloomberg Transatlantic Top 50 Biotech Price Return Index is composed of the largest 25 companies classified in Biotech from Europe DM and North America regions.

 
Details
Formation Date: 21 Jun 2023
Sector: Exchange Traded Notes
JSE Code: BIOTEC
ISIN: ZAE000323481
Currency: South African Rand
Benchmark: Bloomberg Transatlantic Top50 Biotech Net Return Index EUR
Holdings: n/a
Unit Holders: n/a
Original Price: n/a
Pricing System: Forward
Minimum Lump Sum: n/a
n/a

Fees
TER: n/a
Annual: %
Performance: n/a
 
Price
Performance to 1 Dec 2023
R1 000 Lumpsum (NAV-NAV Incl. Dividends)
Period Return Value(R) Inflation(R)
3 Months 0.00% 1 000.00 1 020.80
6 Months - - 1 034.60
 
R100 per Month (NAV-NAV Incl. Dividends)
Period Return Value(R) Inflation(R)
3 Months -0.00% 300.00 303.90
6 Months -0.00% 600.00 613.27
* Values for periods greater than one year are annualised
 
Price
Back to Top

ProfileData has taken care in preparing this information but
does not accept any liability for errors or out-of-date information.
© Copyright Reserved 2023  ]